InMed Pharmaceuticals (INM) Other Accumulated Expenses (2021 - 2023)

InMed Pharmaceuticals has reported Other Accumulated Expenses for 3 years, with the latest figure at $2.3 million in Q1 2023.

• For the quarter ending Q1 2023, Other Accumulated Expenses changed N/A year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2023 stood at $2.3 million (changed N/A YoY), and the FY2022 full-year result was $3.2 million, up 43.6% from the prior year.
• Other Accumulated Expenses for Q1 2023 stood at $2.3 million, down from $2.4 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.3 million in Q3 2022, with the low at $2.2 million in Q2 2021.
• Historically, Other Accumulated Expenses has averaged $2.7 million across 3 years, with a median of $2.4 million in 2022.
• The largest YoY upside for Other Accumulated Expenses was 43.6% in 2022 against a maximum downside of 43.6% in 2022.
• InMed Pharmaceuticals' Other Accumulated Expenses stood at $2.2 million in 2021, then grew by 8.37% to $2.4 million in 2022, then declined by 5.46% to $2.3 million in 2023.
• The last three Other Accumulated Expenses figures came in at $2.3 million (Q1 2023), $2.4 million (Q4 2022), and $3.3 million (Q3 2022), per Business Quant data.